Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
This book chapter provides a comprehensive overview of the pathophysiological mechanisms, biomarkers, and preventive strategies for doxorubicin-induced cardiomyopathy.
Doxorubicin (DOX) is one of the most effective antineoplastic drugs.However, its clinical use is largely limited by potential dose-dependent cardiotoxicity.To date, the mechanisms of DOX-induced cardiotoxicity remains incompletely understood.More importantly, no efficient therapeutic strategy is available to counteract DOX-induced cardiomyopathy, underscoring the importance of the prevention of this disease.In this chapter, we first describe the pathophysiology of DOX-induced cardiotoxicity.We then update the findings of molecular biology of DOX-induced cardiomyopathy including molecular mechanisms, established and putative biomarkers for early diagnosis, and potential genetic factors for prediction of susceptibility.Finally, we introduce a number of pharmaceutical measures and practical lifestyle modifications for the prevention of this disease.
No takes yet. Share an insight, caveat, or question.
Silber et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: